The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

The FDA has approved the first at-home cervical cancer test and weight loss drugs could reduce obesity related cancers.